The latest information and guideline updates that healthcare professionals need to know for their practice are included in the recent AHA/ACC/Multisociety Blood Cholesterol Guidelines. These guidelines also introduce female-specific risk enhancers to help assess cardiovascular risk in women and discuss several new options for lowering LDL-C. Also examined is the new treatment option available for those with elevated triglyceride levels at risk of ASCVD events. The results from the REDUCE-IT trial on icosapent ethyl have led to new FDA indications and updates to many guidelines that now incorporate its use for patients with a high risk of a serious event and an elevated triglyceride level. The key takeaway from this expert dialogue is that lipid management has been redefined.
In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Eliot A. Brinton, MD, FAHA, FNLA, FACE
Utah Lipid Center
Salt Lake City, UT
Consulting Fees: Amarin, Esperion, Kowa
Commercial Interest Speakers Bureau: Amarin, Amgen, Boehringer, Kowa, Merck, Nova, Regeneron, Sanofi
Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Associate Professor of Medicine and Epidemiology
Director of Women's Cardiovascular Health
Associate Director of Preventive Cardiology
Associate Faculty of the Welch Center for Prevention, Epidemiology, and Clinical Research
Division of Cardiology
Johns Hopkins University School of Medicine
No relationships reported
- Sean T. Barrett has nothing to disclose.
- Ben Caref, PhD, has nothing to disclose.
- Amanda Hilferty has nothing to disclose.
- Kathy Wickman has nothing to disclose.
After participating in this educational activity, participants should be better able to:
- Screen and diagnose female patients at high risk of cardiovascular events during their annual visit
- Describe the importance of triglyceride management in ASCVD risk assessment and management
- Apply evidence-based guidelines and recent randomized clinical trial evidence of icosapent ethyl in addition to statin therapy to manage women at risk of ASCVD events
This activity is designed to meet the educational needs of physicians, nurse practitioners, physician assistants, nurses, and certified nurse midwives in the fields of obstetrics and gynecology, family practice, and internal medicine.
Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Global Learning Collaborative designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.
Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.
This activity is supported by an independent educational grant from Amarin Pharma, Inc.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC, Omnia Education, and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education or Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Nanette F. Santoro, MDPeer